Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.51
CLVS's Cash to Debt is ranked higher than
58% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. CLVS: 1.51 )
CLVS' s 10-Year Cash to Debt Range
Min: 0.91   Max: No Debt
Current: 1.51

F-Score: 2
Z-Score: 2.98
M-Score: -8.39
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1425.33
CLVS's Operating margin (%) is ranked higher than
56% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -82.48 vs. CLVS: -1425.33 )
CLVS' s 10-Year Operating margin (%) Range
Min: -1163   Max: -1163
Current: -1425.33

Net-margin (%) -1412.53
CLVS's Net-margin (%) is ranked higher than
56% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. CLVS: -1412.53 )
CLVS' s 10-Year Net-margin (%) Range
Min: -1174.54   Max: -1174.54
Current: -1412.53

ROE (%) -51.00
CLVS's ROE (%) is ranked higher than
65% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. CLVS: -51.00 )
CLVS' s 10-Year ROE (%) Range
Min: -144.26   Max: -26.78
Current: -51

-144.26
-26.78
ROA (%) -27.10
CLVS's ROA (%) is ranked higher than
71% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. CLVS: -27.10 )
CLVS' s 10-Year ROA (%) Range
Min: -65.51   Max: -21.25
Current: -27.1

-65.51
-21.25
ROC (Joel Greenblatt) (%) -8599.81
CLVS's ROC (Joel Greenblatt) (%) is ranked higher than
53% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. CLVS: -8599.81 )
CLVS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8628.31   Max: -4951.81
Current: -8599.81

-8628.31
-4951.81
» CLVS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

CLVS Guru Trades in Q1 2014

Steven Cohen 458,238 sh (-60.72%)
» More
Q3 2014

CLVS Guru Trades in Q3 2014

Jim Simons 22,000 sh (New)
» More
Q4 2014

CLVS Guru Trades in Q4 2014

Jim Simons Sold Out
» More
Q1 2015

CLVS Guru Trades in Q1 2015

Steven Cohen 100,000 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with CLVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 12.00
CLVS's P/B is ranked lower than
52% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. CLVS: 12.00 )
CLVS' s 10-Year P/B Range
Min: 2.83   Max: 12.6
Current: 12

2.83
12.6
EV-to-EBIT -15.49
CLVS's EV-to-EBIT is ranked higher than
53% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. CLVS: -15.49 )
CLVS' s 10-Year EV-to-EBIT Range
Min: -26.2   Max: -8.7
Current: -15.49

-26.2
-8.7
Current Ratio 7.93
CLVS's Current Ratio is ranked higher than
83% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. CLVS: 7.93 )
CLVS' s 10-Year Current Ratio Range
Min: 0.86   Max: 31.09
Current: 7.93

0.86
31.09
Quick Ratio 7.93
CLVS's Quick Ratio is ranked higher than
83% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CLVS: 7.93 )
CLVS' s 10-Year Quick Ratio Range
Min: 0.86   Max: 31.09
Current: 7.93

0.86
31.09
Days Sales Outstanding 75.73
CLVS's Days Sales Outstanding is ranked higher than
80% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. CLVS: 75.73 )
CLVS' s 10-Year Days Sales Outstanding Range
Min: 0   Max: 0
Current: 75.73

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 476.50
CLVS's Price/Tangible Book is ranked lower than
64% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 10.40 vs. CLVS: 476.50 )
CLVS' s 10-Year Price/Tangible Book Range
Min: 2.39   Max: 15.53
Current: 476.5

2.39
15.53
Earnings Yield (Greenblatt) -6.50
CLVS's Earnings Yield (Greenblatt) is ranked higher than
65% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. CLVS: -6.50 )
CLVS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -7.7   Max: 0
Current: -6.5

-7.7
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:C6O.Germany,
Clovis Oncology Inc, a corporation in the development stage, was incorporated in Delaware on April 20, 2009, and commenced operations in May 2009. The Company is a biopharmaceutical company engaged in acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is considered to be in the development stage as of December 31, 2013. The Company has three product candidates in clinical development: CO-1686, which is in Phase I/II development for the treatment of non-small cell lung cancer; rucaparib, which is in Phase II and Phase III clinical trials for the treatment of ovarian cancer; and lucitanib, which is commencing Phase II clinical trials for the treatment of breast and lung cancers. The Company maintains global rights for CO-1686 and rucaparib, and U.S. and Japanese rights to lucitanib.
» More Articles for CLVS

Headlines

Articles On GuruFocus.com
J.P. Morgan’s 3 Biotechnology Picks Apr 14 2015 
VBI Vaccines (VBIV) and Clovis Oncology (CLVS) Momentum Indicators; Wynn Resorts (WYNN) Power Battle Apr 07 2015 
comment on CLVS Mar 06 2013 

More From Other Websites
CLOVIS ONCOLOGY, INC. Financials May 16 2015
Why Clovis is Getting Clobbered May 15 2015
Piper Jaffray Downgrades Clovis Oncology, Asks 'Point Of Maximal Optimism?' May 15 2015
Top Analyst Upgrades and Downgrades: Apple, Clovis, Deere, JC Penney, Wynn, Yum and More May 15 2015
Clovis Oncology (CLVS) Jumps: Stock Adds 16.7% in Session - Tale of the Tape May 15 2015
Clovis Oncology downgraded by Piper Jaffray May 15 2015
The 5 Winners and Losers From ASCO Presentations May 14 2015
Clovis Oncology Announces Data Presentations at 2015 ASCO Annual Meeting May 13 2015
Clovis Oncology Announces Data Presentations at 2015 ASCO Annual Meeting May 13 2015
Biotech to watch ahead of ASCO May 13 2015
CLOVIS ONCOLOGY, INC. Files SEC form 10-Q, Quarterly Report May 08 2015
Biotech stocks to watch: BMY, CLVS & more May 07 2015
Clovis reports 1Q loss May 06 2015
Clovis Oncology Announces First Quarter 2015 Operating Results May 06 2015
Clovis Oncology Inc Earnings Call scheduled for 4:30 pm ET today May 06 2015
Clovis Oncology Announces First Quarter 2015 Operating Results May 06 2015
CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 06 2015
Goldman Sachs Previews ASCO Cancer Conference With Amgen, Celgene And Clovis Oncology May 06 2015
Q1 2015 Clovis Oncology Inc Earnings Release - After Market Close May 06 2015
5 Biotech Stocks to Avoid After Monday's Slump - Analyst Blog Apr 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK